# US 2019/0167763 A1 · Topical pharmaceutical composition for promoting hair growth and/or reducing hair loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167763 A1
- Document ID: US20190167763A1
- Status: Published application
- Kind: A1
- Application number: 16/318,354
- Filed: 2017-07-19
- Published: 2019-06-06
- Earliest claimed: 2016-07-21
- Inventors: Habil F KHORAKIWALA; Vijay SHARMA; Zahabiya KHORAKIWALA
- Web page: https://patentgrep.com/patent/US20190167763A1

## CPC

- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 8/983: {Blood, e.g. plasma}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 35/19: Platelets; Megacaryocytes
- A61K 38/178: {Lectin superfamily, e.g. selectins}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 17/14: for baldness or alopecia
- A61Q 7/00: Preparations for affecting hair growth
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The invention relates to a topical pharmaceutical composition for promoting hair growth and/or reducing hair loss in a human. In particular, the pharmaceutical composition comprises: (A) therapeutically effective amount of platelet component that includes a growth factor concentrate comprising platelet derived growth factor (PGDF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and transforming growth factor-β (TGF-β); and (B) a permeability enhancing agent.

## Claims

### Claim 1

A topical pharmaceutical composition for promoting hair growth and/or reducing hair loss in a human, said composition comprising (A) a platelet component that includes a growth factor concentrate containing (i) about 6,000 pg/mL to about 90,000 pg/mL of platelet derived growth factor (PDGF), and (ii) about 600 pg/mL to about 4,000 pg/mL of vascular endothelial growth factor (VEGF).

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the growth factor concentrate further comprises (a) about 20 pg/mL to about 60 pg/mL of fibroblast growth factor (FGF), and (b) about 80,000 pg/mL to about 140,000 pg/mL of transforming growth factor-β (TGF-β).

### Claim 3 (depends on 1)

The topical pharmaceutical composition according to claim 1, wherein the composition further comprises a permeability enhancing agent.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the growth factor concentrate further comprises (a) about 30 to about 40 pg/mL of fibroblast growth factor (FGF), and (b) about 95,000 to about 110,000 pg/mL of transforming growth factor-β (TGF-β).

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the growth factor concentrate further comprises about 100 ng/mL to about 500 ng/mL of P-selectin.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the growth factor concentrate further comprises about 120 to about 400 ng/mL of P-selectin.

### Claim 7 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the permeability enhancing agent comprises amino acids, surfactants, solvents, essential oils, lower alkanols, or a mixture thereof.

### Claim 8 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the platelet component is of autologous or allogeneic origin.

### Claim 9 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition is applied externally onto scalp of the human in need thereof.

### Claim 10 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition is in the form of a solution, suspension, emulsion, ointment, foam, paste, gel, cream, lotion, spray, powder, or soap.

### Claim 11 (depends on 3)

A process of preparing the topical pharmaceutical composition according to claim 3, wherein the process comprises steps of:
a) extracting the plasma containing platelets from blood of a human by centrifugation of blood at about 2000-8000 rpm for about 2-15 minutes;
b) clotting the platelets in the plasma by adding calcium solution to obtain growth factor concentrate;
c) transferring the obtained growth factor concentrate devoid of any platelet debris in to another container; and
d) mixing of permeability enhancing agent and optionally, one or more pharmaceutically acceptable excipient with the growth factor concentrate of step c) to obtain the topical pharmaceutical composition.

### Claim 12 (depends on 1)

A method of treatment for promoting hair growth and/or reducing hair loss in a human by applying to the scalp of the human the topical pharmaceutical composition according to claim 1.

### Claim 13 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the permeability enhancing agent comprises polyethylene glycol, dimethyl formamide or a mixture thereof.

### Claim 14

A topical pharmaceutical composition for promoting hair growth and/or reducing hair loss in a human said composition comprising (A) a platelet component that includes a growth factor concentrate containing (i) about 6,000 pg/mL to about 90,000 pg/mL of platelet derived growth factor (PDGF), (ii) about 600 pg/mL to about 4,000 pg/mL of vascular endothelial growth factor (VEGF), (iii) about 20 pg/mL to about 60 pg/mL of fibroblast growth factor (FGF), (iv) about 80,000 pg/mL to about 140,000 pg/mL of transforming growth factor-β (TGF-β), and (v) about 100 ng/mL to about 500 ng/mL of P-selectin.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the composition further comprises permeability enhancing agent comprising about (i) 1 mL to about 2 mL of polyethelene glycol and (ii) about 0.5 mL to about 1.5 mL of dimethylformamide.
